Healthcare Providers and Services
Company Overview of Cancer Treatment Centers of America, Inc.
Cancer Treatment Centers of America, Inc. owns and operates cancer care hospitals. It offers medical oncology, surgical oncology, radiation oncology, hematologic oncology, and neurosurgery services; nutrition therapy, pain management, naturopathic medicine, mind-body medicine, oncology rehabilitation, and spiritual support; care management, patient relations, culinary services, outpatient accommodations, transportation, and activities and classes services; acupuncture, chiropractic care, survivorship support, patient education, pharmacy, and HCAHPS comparison services; and interventional pulmonology, gastroenterology, and interventional radiology services. Cancer Treatment Centers of America...
1336 Basswood Road
Schaumburg, IL 60173
Founded in 1988
Key Executives for Cancer Treatment Centers of America, Inc.
Chief Executive Officer and President
Founder and Chairman of the Board
Chief Medical Information Officer, Senior Vice President of Information Services and Naturopathic Physician
Chief Executive Officer of Eastern Regional Medical Center and President of Eastern Regional Medical Center
Compensation as of Fiscal Year 2015.
Cancer Treatment Centers of America, Inc. Key Developments
Cancer Treatment Centers of America Appoints Rodney Huebbers as Chief Operating Officer
Jun 1 15
Cancer Treatment Centers of America (CTCA) announced the appointment of Rodney Huebbers as Chief Operating Officer. Beginning June 15, Huebbers, who will be based at CTCA headquarters in Boca Raton, Fla., will focus on the development and implementation of clinical programs throughout the CTCA enterprise. In his new role, he will provide leadership, resources and focused execution on clinical quality, research, innovation and strategy while working closely with the CTCA Chief Operating Officer, Chief Nursing Officer, Chief Medical Director and regional medical centers' executive leadership teams. Huebbers has more than 30 years of senior-level experience and most recently served as President and Chief Executive Officer of University Health System in Shreveport, La., where he orchestrated the transition and conversion of University Health System from a public entity to a private, not-for-profit health system subsidiary.
Cancer Treatment Centers of America Launches Phase IIi of Innovative ‘Pembroplus’ Clinical Trial
Apr 27 15
Cancer Treatment Centers of America has begun the Phase II portion of the first of six arms of this first-of-its-kind clinical trial, using a new immunotherapy treatment for patients with advanced small cell lung cancer, pancreatic cancer and connective-tissue cancers, including breast cancer. This innovative “PembroPlus” clinical trial combines an immunotherapy drug with already FDA-approved chemotherapy drugs (gemcitabine, docetaxel, nab-paclitaxel, vinorelbine, irinotecan, and/or liposomal doxorubicin). The addition of pembrolizumab is aimed at activating the body’s own immune system to improve the results that otherwise might be achieved from chemotherapy alone. This combination of chemotherapy drugs is investigational in this study. A patient with advanced-stage triple negative breast cancer received the first Phase II treatment on April 23. Triple negative breast cancer is one of the most aggressive and difficult to treat of all breast cancers. The term triple negative refers to the fact that this type of cancer tests negative for estrogen receptors, progesterone receptors and the HER2 protein, and therefore does not respond to hormonal therapy or therapies that target HER2 receptors. Studies have shown that triple negative breast cancer is more likely to spread beyond the breast and more likely to recur after initial treatment. The study will enroll up to 140 patients who have exhausted previous standard-of-care treatments and are now eligible for clinical trial studies. It includes patients with advanced small cell lung cancer, pancreatic cancer, breast cancer, and a variety of sarcomas, which are cancers of the body’s connective tissues, including muscles, fat, nerves and bones.
Cancer Treatment Centers of America Launches Clinical Trial Combining Chemotherapy and Immunotherapy
Jan 14 15
Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona is now accepting patients into a clinical trial that combines more traditional chemotherapy drugs (gemcitabine, docetaxel, nab-paclitaxel, vinorelbine, irinotecan, and/or liposomal doxorubicin) with immunotherapy (pembrolizumab), activating the body’s own immune system to improve upon results that may be achieved from chemotherapy alone. Uniquely, the PembroPlus Phase Ib and Phase II study will target patients with advanced metastatic sarcoma, small cell lung cancer, and pancreatic adenocarcinoma. There are anticipated to be up to 140 patients enrolled on this multi-arm study. Recent data reported in the New England Journal of Medicine1 and Lancet2 demonstrates promising results with antibody-based immunostimulatory therapy in treating melanoma, renal cell carcinoma, and non-small cell lung cancer. Data has also shown synergetic effects of utilizing cytotoxic chemotherapy in combination with immunostimulatory therapy. PembroPlus will build upon this data, extending treatment options to additional cancer types.
Similar Private Companies By Industry
Recent Private Companies Transactions